Cytogenetic characterization of the murine bladder cancer model MB49 and the derived invasive line MB49-I

Cancer Genetics

Volumn 205, Issue 4, 2012, Pages 168-176

  Fabris, Victoria T ^a   Lodillinsky, Catalina ^b   Pampena, María Betina ^a   Belgorosky, Denise ^b   Lanari, Claudia ^a   Eiján, Ana María ^b  

^a Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Bladder cancer; Cytogenetics; FISH; MB49; MB49 I

Indexed keywords

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLADDER CANCER; CANCER CELL CULTURE; CANCER GROWTH; CELL STRAIN MB49; CELL STRAIN MB49 I; CHROMOSOME 19; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHROMOSOME TRANSLOCATION 5; CHROMOSOME TRANSLOCATION 9; CONTROLLED STUDY; CYTOGENETICS; DIPLOIDY; FLUORESCENCE IN SITU HYBRIDIZATION; G BANDING; ISOCHROMOSOME; KARYOTYPE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TETRAPLOIDY; ANIMAL; BLADDER; BLADDER TUMOR; CHROMOSOME; CHROMOSOME BANDING PATTERN; DISEASE COURSE; DISEASE MODEL; GENE DELETION; GENE TRANSLOCATION; GENETICS; KARYOTYPING; PATHOLOGY; TUMOR CELL LINE;

MURINAE;

ANIMALS; CELL LINE, TUMOR; CHROMOSOME ABERRATIONS; CHROMOSOME BANDING; CHROMOSOMES, MAMMALIAN; CYTOGENETIC ANALYSIS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; IN SITU HYBRIDIZATION, FLUORESCENCE; KARYOTYPING; MICE; SEQUENCE DELETION; TRANSLOCATION, GENETIC; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 84862742421     PISSN: 22107762     EISSN: 22107770     Source Type: Journal    
DOI: 10.1016/j.cancergen.2012.02.002     Document Type: Article

References (32)

1. Kakehi Y., Hirao Y., Kim W.J., et al. Bladder Cancer Working Group report. Jpn J Clin Oncol 2010, 40(Suppl. 1):i57-i64.
2. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2006. CA Cancer J Clin 2006, 56:106-130.
3. Lerner S.P. Bladder cancer clinical trials. Urol Oncol 2005, 23:275-279.
4. Lopez-Beltran A., Montironi R. Non-invasive urothelial neoplasms: according to the most recent WHO classification. Eur Urol 2004, 46:170-176.
5. Montironi R., Lopez-Beltran A. The 2004 WHO classification of bladder tumors: a summary and commentary. Int J Surg Pathol 2005, 13:143-153.
6. Cordon-Cardo C. Molecular alterations associated with bladder cancer initiation and progression. Scand J Urol Nephrol Suppl 2008, 218:154-165.
7. Song M.J., Lee H.M., Kim S.H. Clinical usefulness of fluorescence in situ hybridization for diagnosis and surveillance of bladder cancer. Cancer Genet Cytogenet 2010, 198:144-150.
8. Sandberg A.A. Cytogenetics and molecular genetics of bladder cancer: a personal view. Am J Med Genet 2002, 115:173-182.
9. Wolff D.J. The genetics of bladder cancer: a cytogeneticist's perspective. Cytogenet Genome Res 2007, 118:177-181.
10. Placer J., Espinet B., Salido M., et al. Correlation between histologic findings and cytogenetic abnormalities in bladder carcinoma: a FISH study. Urology 2005, 65:913-918.
11. Zieger K., Wiuf C., Jensen K.M., et al. Chromosomal imbalance in the progression of high-risk non-muscle invasive bladder cancer. BMC Cancer 2009, 9:149-160.
12. Chen F., Zhang G., Cao Y., et al. MB49 murine urothelial carcinoma: molecular and phenotypic comparison to human cell lines as a model of the direct tumor response to bacillus Calmette-Guerin. J Urol 2009, 182:2932-2937.
13. Summerhayes I.C., Franks L.M. Effects of donor age on neoplastic transformation of adult mouse bladder epithelium in vitro. J Natl Cancer Inst 1979, 62:1017-1023.
14. Lodillinsky C., Rodriguez V., Vauthay L., et al. Novel invasive orthotopic bladder cancer model with high cathepsin B activity resembling human bladder cancer. J Urol 2009, 182:749-755.
15. Seabright M. A rapid banding technique for human chromosomes. Lancet 1971, 2:971-972.
16. Standard karyotype of the mouse, Mus musculus. J Hered 1972, 63:69-72. Commitee on Standardized Genetic Nomenclature for mice.
17. Dinney C.P., Fishbeck R., Singh R.K., et al. Isolation and characterization of metastatic variants from human transitional cell carcinoma passaged by orthotopic implantation in athymic nude mice. J Urol 1995, 154:1532-1538.
18. Gildea J.J., Golden W.L., Harding M.A., et al. Genetic and phenotypic changes associated with the acquisition of tumorigenicity in human bladder cancer. Genes Chromosomes Cancer 2000, 27:252-263.
19. Harding M.A., Arden K.C., Gildea J.W., et al. Functional genomic comparison of lineage-related human bladder cancer cell lines with differing tumorigenic and metastatic potentials by spectral karyotyping, comparative genomic hybridization, and a novel method of positional expression profiling. Cancer Res 2002, 62:6981-6989.
20. Makridakis M., Gagos S., Petrolekas A., et al. Chromosomal and proteome analysis of a new T24-based cell line model for aggressive bladder cancer. Proteomics 2009, 9:287-298.
21. Savic S., Zlobec I., Thalmann G.N., et al. The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette-Guérin therapy. Int J Cancer 2009, 124:2899-2904.
22. Hill K.S., Lorinczi M., Elferink L.A. Altered down regulation of the receptor tyrosine kinase met in pancreatic adenocarcinoma cells. J Exp Ther Oncol 2010, 8:297-312.
23. Toschi L., Cappuzzo F. Clinical implications of MET gene copy number in lung cancer. Future Oncol 2010, 6:239-247.
24. Cheng H.L., Trink B., Tzai T.S., et al. Overexpression of c-met as a prognostic indicator for transitional cell carcinoma of the urinary bladder: a comparison with p53 nuclear accumulation. J Clin Oncol 2002, 20:1544-1550.
25. Little A.S., Balmanno K., Sale M.J., et al. Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells. Sci Signal 2011, 4:ra17.
26. Wagner P.L., Stiedl A.C., Wilbertz T., et al. Frequency and clinicopathologic correlates of KRAS amplification in non-small cell lung carcinoma. Lung Cancer 2011, 74:118-123.
27. Simon R., Richter J., Wagner U., et al. High-throughput tissue microarray analysis of 3p25 (RAF1) and 8p12 (FGFR1) copy number alterations in urinary bladder cancer. Cancer Res 2001, 61:4514-4519.
28. Panani A.D., Ferti A.D., Raptis S.A., et al. Novel recurrent structural chromosomal aberrations in primary bladder cancer. Anticancer Res 2004, 24:2967-2974.
29. Williams S.V., Platt F.M., Hurst C.D., et al. High-resolution analysis of genomic alteration on chromosome arm 8p in urothelial carcinoma. Genes Chromosomes Cancer 2010, 49:642-659.
30. Mickey D.D., Mickey G.H., Murphy W.M., et al. In vitro characterization of four N-[4-(5-nitro-2-furyl)-2-thiazolyl] formamide (FANFT) induced mouse bladder tumors. J Urol 1982, 127:1233-1237.
31. Minner S., Kilgué A., Stahl P., et al. Y chromosome loss is a frequent early event in urothelial bladder cancer. Pathology 2010, 42:356-359.
32. Tomovska S., Richter J., Süess K., et al. Molecular cytogenetic alterations associated with rapid tumor cell proliferation in advanced urinary bladder cancer. Int J Oncol 2001, 18:1239-1244.